Thermo Fisher Scientific Inc. (TMO) – Mismatched value: Check Out the Fundamental Analysis

In yesterday’s Wall Street session, Thermo Fisher Scientific Inc. (NYSE:TMO) shares traded at $510.72, down -2.74% from the previous session.

As of this writing, 25 analysts cover Thermo Fisher Scientific Inc. (NYSE:TMO). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $700.00 and a low of $505.00, we find $630.00. Given the previous closing price of $525.10, this indicates a potential upside of 19.98 percent. TMO stock price is now -7.86% away from the 50-day moving average and -7.18% away from the 200-day moving average. The market capitalization of the company currently stands at $195.56B.

There are 5 analysts who have given it a hold rating, whereas 16 have given it a buy rating. Brokers who have rated the stock have averaged $624.92 as their price target over the next twelve months.

.

In other news, CASPER MARC N, Chairman & CEO sold 1,600 shares of the company’s stock on May 09. The stock was sold for $855,710 at an average price of $534.82. Upon completion of the transaction, the Chairman & CEO now directly owns 141,330 shares in the company, valued at $72.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 08, Chairman & CEO CASPER MARC N sold 10,000 shares of the business’s stock. A total of $5,444,003 was realized by selling the stock at an average price of $544.40. This leaves the insider owning 141,330 shares of the company worth $72.18 million. Insiders disposed of 315,295 shares of company stock worth roughly $161.03 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.

There have been several recent changes in the stakes of large investors in TMO stock. A new stake in Thermo Fisher Scientific Inc. shares was purchased by OFI INVEST ASSET MANAGEMENT during the first quarter worth $20,625,475,000. PERPETUAL LTD invested $186,309,000 in shares of TMO during the first quarter. In the first quarter, SUMMIT WEALTH GROUP, LLC acquired a new stake in Thermo Fisher Scientific Inc. valued at approximately $56,224,000. EGERTON CAPITAL (UK) LLP acquired a new stake in TMO for approximately $54,520,000. FARMER STEVEN PATRICK purchased a new stake in TMO valued at around $52,099,000 in the second quarter. In total, there are 3,220 active investors with 91.00% ownership of the company’s stock.

Wednesday morning saw Thermo Fisher Scientific Inc. (NYSE: TMO) opened at $510.00. During the past 12 months, Thermo Fisher Scientific Inc. has had a low of $475.77 and a high of $611.06. As of last week, the company has a debt-to-equity ratio of 0.83, a current ratio of 1.30, and a quick ratio of 0.90. According to the stock market information, the enterprise value for the company is $231.59B, which is based on a 33.27 price-to-earnings ratio, a 3.88 price-to-earnings-growth ratio, and a beta of 0.80. The fifty day moving average price for TMO is $553.39 and a two-hundred day moving average price translates $549.84 for the stock.

The latest earnings results from Thermo Fisher Scientific Inc. (NYSE: TMO) was released for Mar, 2023. According to the Diagnostics & Research Company, earnings per share came in at $5.03, inline with analysts’ expectations of $5.03. This compares to $5.62 EPS in the same period last year. The net profit margin was 13.80% and return on equity was 14.00% for TMO. The company reported revenue of $10.71 billion for the quarter, compared to $11.82 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -9.38 percent. For the current quarter, analysts expect TMO to generate $11B in revenue.

Moreover, the firm recently paid out its quarterly dividend on 04/14/2023. Investors who held shares on 03/15/2023 were paid a $0.35 dividend. On an annualized basis, this represents a $1.40 dividend and a 0.27% percent yield. There was an ex-dividend date of 03/14/2023 for this dividend. In terms of dividend payout ratio, TMO is presently at 7.80%.

Thermo Fisher Scientific Inc.(TMO) Company Profile

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company’s Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.